Cost-Effectiveness of PD-L1 Testing in Non-Small Cell Lung Cancer (NSCLC) Using In Vitro Diagnostic (IVD) Versus Laboratory-Developed Test (LDT)
Tóm tắt
Accurate PD-L1 testing for non-small cell lung cancer (NSCLC) maximizes the benefits of immune checkpoint inhibitor (ICI) drugs like pembrolizumab. False negative test results deny ICI treatments to eligible patients, worsening clinical and economic outcomes, while false positives increase costs by using ICI treatments without their benefits. This study evaluates the cost-effectiveness of PD-L1 testing with an in vitro diagnostic (IVD) compared to a laboratory-developed test (LDT) for allocating patients with NSCLC to treatment with either pembrolizumab or chemotherapy using the German healthcare system as a model. We developed a decision analytical model to evaluate the cost-effectiveness of PD-L1 testing with a regulatory body approved IVD compared to an LDT from the national German healthcare payer (statutory health insurance system) perspective. Accuracy of PD-L1 testing was based on data from two independent proficiency testing programs. The 1-year model was based on outcomes data from the KEYNOTE-024 clinical trial and treatment patterns reflecting current German practices. IVDs produced accurate PD-L1 testing results in 93% (752/811) of tested cases compared to 73% (492/672) with LDTs. Most misclassifications concerned false negatives, occurring in 21% of LDTs vs 7% of IVDs. Total costs of the IVD group (48,878 €) were 196 € higher than the LDT group (48,682 €). These costs incorporate testing, first- and second-line therapy, managing treatment-related grade 3+ adverse events (AEs), and end-of-life costs for those who died within the year. Total effectiveness (percentage of patients successfully diagnosed and prescribed the correct therapy per German treatment guidelines) was 19 percentage points higher for the IVD group (88%) compared to the LDT group (69%). These differences in costs and effects lead to an incremental cost-effectiveness ratio (ICER) of 1057 €. Compared to LDT technology, on-label IVD use for PD-L1 testing is only slightly more costly and substantially more effective for aligning patients with PD-L1-positive NSCLC with ICI therapy according to German practice guidelines. Given these findings, changes to testing and reimbursement policies may be considered to maximize patient outcomes in NSCLC.
Tài liệu tham khảo
Sharpe AH, Freeman GJ. The B7-CD28 superfamily. Nat Rev Immunol. 2002;2:116–26.
Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677–704.
Dong H, Strome SE, Salomao DR, et al. Tumor-associated B7–H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat Med. 2002;8:793–800.
Freeman GJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med. 2000;192:1027–34.
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.
Herbst RS, Baas P, Kim D-W, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387:1540–50.
Mok TSK, Wu Y-L, Kudaba I, et al. Pembrolizumab versus chemotherapy for previously untreated, PD-L1-expressing, locally advanced or metastatic non-small-cell lung cancer (KEYNOTE-042): a randomised, open-label, controlled, phase 3 trial. Lancet. 2019;393:1819–30.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N Engl J Med. 2016;375:1823–33. https://doi.org/10.1056/NEJMoa1606774.
Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. N Engl J Med. 2015;373:1627–39.
Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372:2018–28.
Onoi K, Chihara Y, Uchino J, et al. Immune checkpoint inhibitors for lung cancer treatment: a review. J Clin Med. 2020. https://doi.org/10.3390/jcm9051362.
Rittmeyer A, Barlesi F, Waterkamp D, et al. Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial. Lancet. 2017;389:255–65.
Rizvi NA, Cho BC, Reinmuth N, et al. Durvalumab with or without tremelimumab vs standard chemotherapy in first-line treatment of metastatic non-small cell lung cancer: the MYSTIC phase 3 randomized clinical trial. JAMA Oncol. 2020;6:661–74.
Wu Y-L, Lu S, Cheng Y, et al. Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced NSCLC: CheckMate 078 randomized phase III clinical trial. J Thorac Oncol. 2019;14:867–75.
Chen R, Hou X, Yang L, Zhao D. Comparative efficacy and safety of first-line treatments for advanced non-small cell lung cancer with immune checkpoint inhibitors: a systematic review and meta-analysis. Thorac Cancer. 2019;10:607–23.
Khan M, Lin J, Liao G, et al. Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: a meta-analysis of randomized controlled trials. Medicine (Baltimore). 2018;97: e11936.
European Medicines Agency (EMA) (n.d.) Keytruda. https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda. Accessed June 22, 2021.
Griesinger F, Eberhardt W, Fruh M, et al. Lungenkarzinom, nicht-kleinzellig (NSCLC). 2019. https://www.onkopedia.com/de/onkopedia/guidelines/lungenkarzinom-nicht-kleinzellig-nsclc/@@guideline/html/index.html. Accessed 17 Feb 2021.
Sebastian M, Eberhardt WEE, Losem C, et al. 1519P—Patients with metastatic non-small cell lung cancer and PD-L1 expression in Germany: treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315). Ann Oncol. 2019;30: v623. https://doi.org/10.1093/annonc/mdz260.041.
Griesinger F, Eberhardt WEE, Bruch H-R, et al. 1500P—Patients with metastatic non-small cell lung cancer without molecular alterations or PD-L1 expression in Germany: treatment and first outcome from the prospective German Registry Platform CRISP (AIO-TRK-0315). Ann Oncol. 2019;30: v616. https://doi.org/10.1093/annonc/mdz260.022.
Griesinger F, Eberhardt W, Nusch A, et al. Biomarker testing in non-small cell lung cancer in routine care: analysis of the first 3,717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). Lung Cancer. 2021;152:174–84.
Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline from the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142:321–46.
Pennell NA, Arcila ME, Gandara DR, West H. Biomarker testing for patients with advanced non-small cell lung cancer: real-world issues and tough choices. Am Soc Clin Oncol Educ Book. 2019;39:531–42.
Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2018;29(Suppl 4):iv192–237.
Planchard D, Popat S, Kerr K, et al. Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. UPDATED. European Society for Medical Oncology (ESMO). 2020. https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer. Accessed 22 June 2021.
Hayes DF. Considerations for implementation of cancer molecular diagnostics into clinical care. Am Soc Clin Oncol Educ Book. 2016;35:292–6.
Brody R, Zhang Y, Ballas M, et al. PD-L1 expression in advanced NSCLC: Insights into risk stratification and treatment selection from a systematic literature review. Lung Cancer. 2017;112:200–15.
Adam J, Le Stang N, Rouquette I, et al. Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. Ann Oncol. 2018;29:953–8.
Ratcliffe MJ, Sharpe A, Midha A, et al. Agreement between programmed cell death ligand-1 diagnostic assays across multiple protein expression cutoffs in non-small cell lung cancer. Clin Cancer Res. 2017;23:3585–91.
Vigliar E, Malapelle U, Bono F, et al. The reproducibility of the immunohistochemical PD-L1 testing in non-small-cell lung cancer: a multicentric Italian experience. BioMed Res Int. 2019;2019:6832909.
Dodson A, Parry S, Lissenberg-Witte B, et al. External quality assessment demonstrates that PD-L1 22C3 and SP263 assays are systematically different. J Pathol Clin Res. 2020;6:138–45.
Euro-Informationen, Berlin. Krankenkassen-Fusionen: Fusionskalender. 2021. In: Krankenkassen Deutchland. https://www.krankenkassen.de/gesetzliche-krankenkassen/system-gesetzliche-krankenversicherung/fusionen/. Accessed July 27, 2021.
Tikkanen R, Osborn R, Mossialos E, Djordjevic A, Wharton GA. Germany. The Commonwealth Fund. 2020. https://www.commonwealthfund.org/international-health-policy-center/countries/germany. Accessed 22 June 2021.
Oncology guideline program (German Cancer Society, German Cancer Aid, AWMF). Prevention, diagnosis, therapy and follow-up care of lung cancer, long version 1.0. 2018. http://leitlinienprogramm-onkologie.de/Lungenkarzinom.98.0.html. Accessed 22 June 2021.
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Updated analysis of KEYNOTE-024: pembrolizumab versus platinum-based chemotherapy for advanced non-small-cell lung cancer with PD-L1 tumor proportion score of 50% or greater. J Clin Oncol. 2019;37:537–46.
Bekelman JE, Halpern SD, Blankart CR, et al. Comparison of site of death, health care utilization, and hospital expenditures for patients dying with cancer in 7 developed countries. JAMA. 2016;315:272–83. https://doi.org/10.1001/jama.2015.18603.
NordiQC. https://nordiqc.org/index.php. Accessed June 22, 2021.
UK NEQAS. https://ukneqas.org.uk/. Accessed June 22, 2021.
Federal Statistical Office. Consumer price index - Germany, years, individual consumption by purpose (61111-0004). 2021. In: Destatis Stat. Bundesamt Genes. https://www-genesis.destatis.de/genesis/online?operation=statistic&levelindex=0&levelid=1627680794066&code=61111#abreadcrumb. Accessed 30 July 2021.
National Association of Statutory Health Insurance Physicians (KBV). https://www.kbv.de/html/13259.php?srt=relevance&stp=fulltext&q=19320&s=Search. Accessed June 4, 2021.
Federal Joint Committee (G-BA). Beschluss des Gemeinsamen Bundesausschusses uber eine Änderung der Arzneimittel-Richtlinie (AM-RL): Anlage XII—Nutzenbewertung von Arzneimittel mit neuen Wirkstoffen nach § 35a SGB V. Pembrolizumab (neue Anwendungsgebeit: nicht-kleinzelliges Lungenkarinom, plattenepithelial, ErsteLinie, Kombination mit Carboplatin und (nab-) Paclitaxel). 2019. https://www.g-ba.de/downloads/39-261-3958/2019-09-19_AM-RL-XII_Pembrolizumab_D-448_nAWG_BAnz.pdf. Accessed 10 Sept 2020.
Campone M, Yang H, Faust E, et al. Cost of adverse events during treatment with everolimus plus exemestane or single-agent chemotherapy in patients with advanced breast cancer in Western Europe. J Med Econ. 2014;17:837–45. https://doi.org/10.3111/13696998.2014.959589.
Schremser K, Rogowski WH, Adler-Reichel S, Tufman ALH, Huber RM, Stollenwerk B. Cost-effectiveness of an individualized first-line treatment strategy offering erlotinib based on EGFR mutation testing in advanced lung adenocarcinoma patients in Germany. Pharmacoeconomics. 2015;33:1215–28. https://doi.org/10.1007/s40273-015-0305-8.
Wahler S, Müller A, Koll C, Seyed-Abbaszadeh P, Von Der Schulenburg JM. Economic evaluation of adverse events of dabrafenib plus trametinib versus nivolumab in patients with advanced BRAF-mutant cutaneous melanoma for adjuvant therapy in Germany. J Mark Access Health Policy. 2020;9:1861804. https://doi.org/10.1080/20016689.2020.1861804.
Nenadić I, Staber J, Dreier S, et al. Cost saving opportunities in NSCLC therapy by optimized diagnostics. Cancers. 2017. https://doi.org/10.3390/cancers9070088.
Vyberg M, Nielsen S, Røge R, et al. Immunohistochemical expression of HER2 in breast cancer: socioeconomic impact of inaccurate tests. BMC Health Serv Res. 2015;15:352.
Kasztura M, Richard A, Bempong N-E, Loncar D, Flahault A. Cost-effectiveness of precision medicine: a scoping review. Int J Public Health. 2019;64:1261–71.
Cheng MM, Palma JF, Scudder S, Poulios N, Liesenfeld O. The clinical and economic impact of inaccurate EGFR mutation tests in the treatment of metastatic non-small cell lung cancer. J Pers Med. 2017. https://doi.org/10.3390/jpm7030005.
Aguiar PNJ, Perry LA, Penny-Dimri J, et al. The effect of PD-L1 testing on the cost-effectiveness and economic impact of immune checkpoint inhibitors for the second-line treatment of NSCLC. Ann Oncol. 2017;28:2256–63.
Wan N, Zhang T-T, Hua S-H, et al. Cost-effectiveness analysis of pembrolizumab plus chemotherapy with PD-L1 test for the first-line treatment of NSCLC. Cancer Med. 2020;9:1683–93.
Weng X, Luo S, Lin S, et al. Cost-utility analysis of pembrolizumab versus chemotherapy as first-line treatment for metastatic non-small cell lung cancer with different PD-L1 expression levels. Oncol Res. 2020;28:117–25.
European Commission. Guidance on classification rules for in vitro diagnostic medical devices under Regulation (EU) 2017/746. 2020. https://ec.europa.eu/health/sites/health/files/md_sector/docs/md_mdcg_2020_guidance_classification_ivd-md_en.pdf. Accessed 8 Feb 2021.
Dafni U, Tsourti Z, Vervita K, Peters S. Immune checkpoint inhibitors, alone or in combination with chemotherapy, as first-line treatment for advanced non-small cell lung cancer. A systematic review and network meta-analysis. Lung Cancer. 2019;134:127–40.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Non-Small Cell Lung Cancer. 2020. https://www.nccn.org/patients. Accessed 8 Feb 2021.
National Association of Statutory Health Insurance Physicians (KBV: Kassenärztliche Bundesvereinigung). https://www.kbv.de/html/13259.php?srt=relevance&stp=fulltext&q=19320&s=Suchen. Accessed June 4, 2021.
Justification to the Resolution of the Federal Joint Committee (G-BA) on an Amendment of the Pharmaceuticals Directive (AM-RL): Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients According to Section 35a SGB V Pembrolizumab (new therapeutic indication: non-small cell lung carcinoma, non-squamous, first line, combination with pemetrexed and platinum chemotherapy). September 19, 2019. https://www.g-ba.de/bewertungsverfahren/nutzenbewertung/452/#english. Accessed 10 Sept 2020.